The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity

被引:36
作者
Blanter, Julia B. [1 ]
Frishman, William H. [2 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[2] Westchester Med Ctr, New York Med Coll, Dept Med, Valhalla, NY USA
关键词
cardiotoxicity; chemotherapy; beta-adrenergic blockers; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; VENTRICULAR SYSTOLIC DYSFUNCTION; BREAST-CANCER; HEART-FAILURE; CARDIO-ONCOLOGY; DOXORUBICIN; CARVEDILOL; THERAPY; CANDESARTAN; ENALAPRIL; TRIAL;
D O I
10.1097/CRD.0000000000000252
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anthracycline (doxorubicin) and trastuzumab treatments for cancer patients have been known to cause cardiotoxicity. The current recommendations for prevention of cardiac events from cancer chemotherapies are largely based on opinion. The American Society of Clinical Oncology recommends active screening and prevention of modifiable cardiovascular risk factors. The risk factors are defined as tobacco use, high blood pressure, high cholesterol, alcohol use, obesity, and physical inactivity. Beta-adrenergic blockers and angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) have been the mainstay of treatment for heart failure patients with reduced left ventricular ejection fraction for many years. This review analyzed the use of beta-adrenergic blockers and ACE inhibitors/ARBs as protection against cardiomyopathy caused by anthracyclines and trastuzumab. Although many more studies are warranted, it was concluded that the addition of a beta-blocker early in the treatment of cancer patients who are undergoing anthracycline or trastuzumab treatment can have beneficial effects in preserving left ventricular ejection fraction and preventing chemotherapy-induced cardiotoxicity. The effects are more apparent in the short term. More studies of the long-term effects are warranted, as are the additive effects of using a beta-blocker and ACE inhibitor/ARB together to prevent chemotherapy-induced cardiotoxicity.
引用
收藏
页码:256 / 259
页数:4
相关论文
共 30 条
[1]   Prevention, Detection, and Management of Chemotherapy-Related Cardiac Dysfunction [J].
Abdel-Qadir, Husam ;
Amir, Eitan ;
Thavendiranathan, Paaladinesh .
CANADIAN JOURNAL OF CARDIOLOGY, 2016, 32 (07) :891-899
[2]   Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity [J].
Avila, Monica Samuel ;
Ayub-Ferreira, Silvia Moreira ;
de Barros Wanderley, Mauro Rogerio, Jr. ;
Cruz, Fatima das Dores ;
Goncalves Brandao, Sara Michelly ;
Carvalho Rigaud, Vagner Oliveira ;
Higuchi-dos-Santos, Marilia Harumi ;
Hajjar, Ludhmila Abrahao ;
Kalil Filho, Roberto ;
Hoff, Paulo Marcelo ;
Sahade, Marina ;
Ferrari, Marcela S. M. ;
de Paula Costa, Romulo Leopoldo ;
Mano, Max Senna ;
Bittencourt Viana Cruz, Cecilia Beatriz ;
Abduch, Maria Cristina ;
Lofrano Alves, Marco Stephan ;
Guimaraes, Guilherme Veiga ;
Issa, Victor Sarli ;
Bittencourt, Marcio Sommer ;
Bocchi, Edimar Alcides .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (20) :2281-2290
[3]   Cardiac Protection in HER2-Targeted Treatment How Should We Measure New Strategies? [J].
Barac, Ana ;
Swain, Sandra M. .
JAMA ONCOLOGY, 2016, 2 (08) :1037-1039
[4]   Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer A Randomized Clinical Trial [J].
Boekhout, Annelies H. ;
Gietema, Jourik A. ;
Kerklaan, Bojana Milojkovic ;
van werkhoven, Erik D. ;
Altena, Renske ;
Honkoop, Aafke ;
Los, Maartje ;
Smit, Willem M. ;
Nieboer, Peter ;
Smorenburg, Carolien H. ;
Mandigers, Caroline M. P. W. ;
van der Wouw, Agnes J. ;
Kessels, Lonneke ;
van der Velden, Annette W. G. ;
Ottevanger, Petronella B. ;
Smilde, Tineke ;
de Boer, Jaap ;
van Veldhuisen, Dirk J. ;
Kema, Ido P. ;
de Vries, Elisabeth G. E. ;
Schellens, Jan H. M. .
JAMA ONCOLOGY, 2016, 2 (08) :1030-1037
[5]   Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies [J].
Bosch, Xavier ;
Rovira, Montserrat ;
Sitges, Marta ;
Domenech, Ariadna ;
Ortiz-Perez, Jose T. ;
de Caralt, Teresa M. ;
Morales-Ruiz, Manuel ;
Perea, Rosario J. ;
Monzo, Mariano ;
Esteve, Jordi .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (23) :2355-2362
[6]   Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition [J].
Cardinale, Daniela ;
Colombo, Alessandro ;
Sandri, Maria T. ;
Lamantia, Giuseppina ;
Colombo, Nicola ;
Civelli, Maurizio ;
Martinelli, Giovanni ;
Veglia, Fabrizio ;
Fiorentini, Cesare ;
Cipolla, Carlo M. .
CIRCULATION, 2006, 114 (23) :2474-2481
[7]   Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy [J].
Cardinale, Daniela ;
Colombo, Alessandro ;
Bacchiani, Giulia ;
Tedeschi, Ines ;
Meroni, Carlo A. ;
Veglia, Fabrizio ;
Civelli, Maurizio ;
Lamantia, Giuseppina ;
Colombo, Nicola ;
Curigliano, Giuseppe ;
Fiorentini, Cesare ;
Cipolla, Carlo M. .
CIRCULATION, 2015, 131 (22) :1981-1988
[8]   The roots of modern oncology: from discovery of new antitumor anthracyclines to their clinical use [J].
Cassinelli, Giuseppe .
TUMORI JOURNAL, 2016, 102 (03) :226-235
[9]   Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy [J].
Chen, Yung-Lung ;
Chung, Sheng-Ying ;
Chai, Han-Tan ;
Chen, Chih-Hung ;
Liu, Chu-Feng ;
Chen, Yi-Ling ;
Huang, Tien-Hung ;
Zhen, Yen-Yi ;
Sung, Pei-Hsun ;
Sun, Cheuk-Kwan ;
Chua, Sarah ;
Lu, Hung-I ;
Lee, Fan-Yen ;
Sheu, Jiunn-Jye ;
Yip, Hon-Kan .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 355 (03) :516-527
[10]   Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone [J].
Damiani, Roberto Marques ;
Moura, Dinara Jaqueline ;
Viau, Cassiana Macagnan ;
Caceres, Rafael Andrade ;
Pegas Henriques, Joao Antonio ;
Saffi, Jenifer .
ARCHIVES OF TOXICOLOGY, 2016, 90 (09) :2063-2076